March 13, 2017 08:09 AM EDT
Pharma

Cel­gene em­braces MTAP can­cer deal with fast-mov­ing col­lab­o­ra­tor Agios

John Carroll

Editor & Founder

Ten months af­ter Cel­gene paid Agios $200 mil­lion to re­jig their ex­ten­sive col­lab­o­ra­tion deal, the big biotech is tak­ing a step for­ward down a me­tab­o­lism …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times